Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Human cancer genomes harbour a variety of alterations leading to the deregulation of key
pathways in tumour cells. The genomic characterization of tumours has uncovered …

With the emergence of genomic profiling technologies and selective molecular targeted
therapies, biomarkers play an increasingly important role in the clinical management of …

Mitotic cell division is tightly monitored by checkpoints that safeguard the genome from
instability. Failures in accurate chromosome segregation during mitosis can cause …

Background Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

These EANO–ESMO joint recommendations for the diagnosis and treatment of
leptomeningeal metastasis (LM) from solid cancers represent the first European guideline …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …